Immunocytochemical Analyses and Targeted Gene Disruption of GTPBP1

Abstract

We previously identified a gene encoding a putative GTPase, GTPBP1, which is structurally related to elongation factor 1␣, a key component of protein biosynthesis machinery. The primary structure of GTPBP1 is highly conserved between human and mouse (97% identical at the amino acid level). Expression of this gene is enhanced by gamma interferon in a monocytic cell line, THP-1. Although counterparts of this molecule in Caenorhabditis elegans and Ascaris suum have also been identified, the function of this molecule remains to be clarified. In the present study, our immunohistochemical analyses on mouse tissues revealed that GTPBP1 is expressed in some neurons and smooth muscle cells of various organs as well as macrophages. Immunofluorescence analyses revealed that GTPBP1 is localized exclusively in cytoplasm and shows a diffuse granular network forming a gradient from the nucleus to the periphery of the cells in smooth muscle cell lines and macrophages. To investigate the physiological role of GTPBP1, we used targeted gene disruption in embryonic stem cells to generate GTPBP1-deficient mice. The mutant mice were born at the expected Mendelian frequency, developed normally, and were fertile. No manifest anatomical or behavioral abnormality was observed in the mutant mice. Functions of macrophages, including chemotaxis, phagocytosis, and nitric oxide production, in mutant mice were equivalent to those seen in wild-type mice. No significant difference was observed in the immune response to protein antigen between mutant mice and wild-type mice, suggesting normal function of antigen-presenting cells of the mutant mice. The absence of an eminent phenotype in GTPBP1-deficient mice may be due to functional compensation by GTPBP2, a molecule we recently identified which is similar to GTPBP1 in structure and tissue distribution.

Prevention of Experimental Autoimmune Encephalomyelitis by Transfer of Embryonic Stem Cell-Derived Dendritic Cells Expressing Myelin Oligodendrocyte Glycoprotein Peptide along with TRAIL or Programmed Death-1 Ligand

“…Immunization of mice and restimulation of draining lymph node cells in vitro were done as described (26), but with some modification. In brief, ES-DC-treated and control mice were immunized at the base of the tail with MOG peptide, according to protocol for EAE induction, or 50 g of KLH protein (Sigma-Aldrich) emulsified in CFA.…”

Embryonic Stem Cell–Derived Dendritic Cells Expressing Glypican-3, a Recently Identified Oncofetal Antigen, Induce Protective Immunity against Highly Metastatic Mouse Melanoma, B16-F10

“…The cells were cultured in RPMI 1640 supplemented with 10% FCS. To produce glypican-3-expressing MCA (MCA-GPC3), MCA cells were transfected with pCAGGS-GPC3-internal ribosomal entry site (IRES)-puromycin-resistant (puro-R) by using LipofectAMINE 2000 reagent (Invitrogen Corp., Carlsbad, CA), selected with puromycin, and then subjected to cloning by limiting dilution in drug-free medium using 96-well culture plates (27,28).…”

HLA-A2 and -A24-restricted glypican-3-derived peptide vaccine induces specific CTLs: Preclinical study using mice

“…The cells were cultured in RPMI-1640 medium supplemented with 10% FCS. To obtain GPC3-expressing RMA-HHD (RMA-HHD-GPC3) cells, RMA-HHD cells were transfected with pCAGGS-GPC3-internal ribosomal entry site (IRES)-puromycin-resistant gene with Lipofectamine 2000 reagent (Invitrogen Corp., Carlsbad, CA), selected with puromycin, and then subjected to cloning by limiting dilution in drug-free medium in 96-well culture plates (12,13). Dendritic cells were obtained from bone marrow cells (BM-DCs) as described previously (4).…”